Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - teriflunomide, quantity: 14 mg - tablet - excipient ingredients: maize starch; lactose monohydrate; sodium starch glycollate; hyprolose; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; indigo carmine aluminium lake - apo-teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rituximab 10 mg/ml - concentrate for infusion - 10 mg/ml - active: rituximab 10 mg/ml excipient: citric acid monohydrate hydrochloric acid polysorbate 80 sodium chloride sodium hydroxide water for injection - latest regulatory activity

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; hydrochloric acid; water for injections; sodium hydroxide; polysorbate 80 - non-hodgkin?s lymphoma (nhl),riximyo (rituximab) is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia (cll),riximyo (rituximab) is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,rheumatoid arthritis (ra),riximyo (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),riximyo (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: water for injections; polysorbate 80; citric acid monohydrate; hydrochloric acid; sodium chloride; sodium hydroxide - non-hodgkin?s lymphoma (nhl),riximyo (rituximab) is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia (cll),riximyo (rituximab) is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,rheumatoid arthritis (ra),riximyo (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),riximyo (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Israel - English - Ministry of Health

medison pharma ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 240 mg - dimetyl fumarate - tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.